(3-Methylisoxazol-4-yl)methanamine hydrochloride
- $421 - $1340
- Product name: (3-Methylisoxazol-4-yl)methanamine hydrochloride
- CAS: 1373029-26-5
- MF: C5H9ClN2O
- MW: 148.59
- EINECS:
- MDL Number:MFCD23378440
- Synonyms:(3-Methylisoxazol-4-yl)methanamine hydrochloride;(3-Methyl-1,2-oxazol-4-yl)methanamine hydrochloride;(3-METHYLISOXAZOL-4-YL)METHANAMINE HCL;(3-Methylisoxazol-4-Yl)Methanamine Hydrochloride(WX603010)
4 prices
Selected condition:
Brand
- Chemenu
- Crysdot
Package
- 1g
- 5g
- ManufacturerChemenu
- Product numberCM323364
- Product description(3-Methylisoxazol-4-yl)methanaminehydrochloride 95%
- Packaging1g
- Price$421
- Updated2021-12-16
- Buy
- ManufacturerChemenu
- Product numberCM323364
- Product description(3-Methylisoxazol-4-yl)methanaminehydrochloride 95%
- Packaging5g
- Price$1262
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11270278
- Product description(3-Methylisoxazol-4-yl)methanaminehydrochloride 95+%
- Packaging1g
- Price$446
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11270278
- Product description(3-Methylisoxazol-4-yl)methanaminehydrochloride 95+%
- Packaging5g
- Price$1340
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
Chemenu | CM323364 | (3-Methylisoxazol-4-yl)methanaminehydrochloride 95% | 1g | $421 | 2021-12-16 | Buy |
Chemenu | CM323364 | (3-Methylisoxazol-4-yl)methanaminehydrochloride 95% | 5g | $1262 | 2021-12-16 | Buy |
Crysdot | CD11270278 | (3-Methylisoxazol-4-yl)methanaminehydrochloride 95+% | 1g | $446 | 2021-12-16 | Buy |
Crysdot | CD11270278 | (3-Methylisoxazol-4-yl)methanaminehydrochloride 95+% | 5g | $1340 | 2021-12-16 | Buy |
Properties
Safety Information
Symbol(GHS): | |||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | ||||||||||||||||||||||||||||||
Hazard statements: |
|
||||||||||||||||||||||||||||||
Precautionary statements: |
|